Glycotest is a liver disease diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis. Founded in 2012 by NetScientific plc on technology originating at the Baruch S. Blumberg Institute and Drexel University College of Medicine, we have exclusive, world-wide rights to over 50 patent-protected serum glycoprotein biomarkers that exploit novel sugar-based disease signals. The Company’s lead test for curable early-stage liver cancer has significantly outperformed the current standard blood test in multiple preliminary clinical studies. Our mission is to revolutionize the care and treatment of the at-risk chronic liver disease population, including the rapidly growing population with NASH.